News & Press

Filter by year:

GeNeuro Announces First Patient Treated in Phase 2a Study with GNbAC1 in Type 1 Diabetes

Geneva, Switzerland, 19 June 2017 - 7:30am CEST : - GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that the first patient has been treated in its Australian Phase 2a study of GNbAC1 in type 1 diabetes. This is GNbAC1’s second indication after multiple sclerosis, for which an international Phase 2b study is ongoing in 260 patients.

GeNeuro Presents Data Supporting Role of Human Endogenous Retroviruses (HERVs) in Type 1 Diabetes at American Diabetes Association (ADA) Scientific Sessions

Geneva (Switzerland), 12 june 2017 - 7:30am CEST : - GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today data supporting the link between human endogenous retroviruses (HERVs) and Type 1 diabetes (T1D). Data were presented at the 77th Scientific Sessions of the American Diabetes Association in San Diego, USA (June 9-13, 2017).

GeNeuro Reports 2016 Full-Year Results and Provides Corporate Update

Geneva (Switzerland), April 27, 2017 : - GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, including multiple sclerosis (MS), today reported its full-year results for the year ended December 31, 2016, and provided a corporate update.

GeNeuro Initiates Phase 2a Study with GNbAC1 in Type 1 Diabetes in Australia

Geneva (Switzerland), April 18, 2017 : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, announced today the initiation of a Phase 2a clinical study in Australia with GNbAC1 in patients with Type 1 diabetes (T1D). GNbAC1 is a monoclonal antibody designed to neutralise MSRV-Env, a pathogenic protein that has been detected in the pancreas of T1D patients.

[Endogenous retroviral sequences in the human genome can play a physiological or pathological role].

Medina J, Charvet B, Leblanc P, Germi R, Horvat B, Marche PN, Perron H, 

Med Sci (Paris). 2017 Apr;33(4):397-403

GeNeuro provides access to presentations from HERVs and disease workshop held in Washington, DC

Geneva (Switzerland), March 28, 2017 : GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), today provided access to research on human endogenous retroviruses (HERVs) and their impact on neurological pathologies.

2017 february - Le Temps «GeNeuro veut devenir un Actelion romand»

La société développe une nouvelle approche pour lutter contre la Sclérose en Plaques. Elle a été identifiée comme un "champion de la croissance" par une étude réalisée par la "Handelszeitung" et "Le Temps", en collaboration avec l'Institut Statista.

GeNeuro Signs CRADA Agreement with NIH to Develop Novel Antibody Treatment for ALS

Geneva (Switzerland), 7 February 2017 : (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological disorders and autoimmune diseases, including multiple sclerosis (MS), announced today the signing of a Cooperative Research and Development Agreement (CRADA) with The National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH), to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis (ALS). The research will evaluate the ability of these antibodies to neutralise a potential causal factor of ALS, the envelope protein of HERV-K (a family of Human Endogenous Retroviruses, HERVs).

[DNA sequences from mobile genetic elements, a hidden half of the human genome].

Medina J, Perron H

Med Sci (Paris). 2017 Feb;33(2):151-158

GeNeuro reports cash and revenue at Dec.31, 2016

Geneva, Switzerland, 31 January 2017 – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis (MS), reports today on its cash and revenue at December 31, 2016.


Results 1-10 of 11      Next Page      Last Page